Abzena provides proprietary technologies and complementary services to organisations involved in the development of biopharmaceutical products.
With a Cambridge HQ at Babraham Research Campus and expanding facilities in California, Abzena works with companies and academic groups all over the world, including most of the top 20 biopharmaceutical businesses. Abzena supports the development and manufacture of better treatments for patients. Twelve antibodies which have been created using Abzena’s technologies are currently being progressed through clinical development.
Abzena incorporates the businesses of Antitope, PacificGMP, PolyTherics, The Chemistry Research Solution (TCRS) and Warwick Effect Polymers, all of which now trade as Abzena. In 2014 Abzena listed on London Stock Exchange AIM market raising £20 million and relocated from London to Cambridge.
Abzena was acquired in 2018 by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors, and delisted from AIM.